Exit
Before you view the poster session, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. What are your credentials? 

Question Title

* 2. What is your specialty?

Question Title

* 3. How confident are you in the management of patients with ALL in your practice?

Question Title

* 4. OA is a 13-year-old male diagnosed with B-cell ALL. 
  • His white blood cell count at diagnosis was 40 x109/L and he did not have CNS involvement.
  • He received induction on UKALL 2003 and his day 8 bone marrow biopsy showed a rapid early response with 5% blasts.
  • At the end of induction his bone marrow biopsy showed MRD < 0.01% and he proceeded with reduced-intensity therapy with 1 delayed intensification followed by maintenance therapy for 2.5 years.
  • At a follow-up appointment 5 years after his diagnosis his parents would like to understand the likelihood of long-term overall survival.
Which of the following is the most appropriate response?

Question Title

* 5. After 10 years of follow-up in the UKALL 2003 trial, augmentation of treatment intensity in children and adolescent young adult (AYA) with acute lymphoblastic leukemia (ALL) and minimal residual disease (MRD) > 0.01% at the end of induction was associated with which of the following outcomes?

Question Title

* 6. Dosing pegaspargase at 500 U/m2 in patients with elevated risk for hepatoxicity on the GMALL Trial 8/2013 was associated with which of the following outcomes?

Question Title

* 7. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity) 

( Privacy & Cookie Notice

T